Inclusion Criteria:

- Cytological and histological confirmation of non-small cell lung cancer (NSCLC)
diagnosis, single sputum cytology diagnosis is not accepted

- Expected survival period is more than 3 months

- Enough blood function reservation: absolute neutrophil count (ANC) 2 x 10E9/L or
higher;platelet count 100 x 109 /L or higher;hemoglobin 9 g/dL or higher.

- Enough liver function reservation:the total bilirubin less than upper limit of
normal;AST and ALT acuities were less than 2.5 times the upper limit of normal
(ULN);Alkaline phosphatase 5 times the upper limit of normal (ULN) or less.

- Clinical doctors identify patients suitable for standard doses of ganglioside drug
therapy, and expected time of medication is at least six weeks

- Within 4 weeks before treatment, did not receive other adverse reaction of drugs may
cause similar neurotoxicity; 18 weeks before, did not received platinum-based drugs
chemical treatment.

- No more than 1 degree of the peripheral nervous system diseases exists before
enrollment, also no other symptom or disease could affect the adverse reactions of
neurotoxicity pathological.

- Can't accept other adverse reactions may prevent neurotoxicity treatment or care
after enrollment.

- Sign the informed consent form.

Exclusion Criteria:

- Patients with poor general condition, PS score more than 2 points

- Women in pregnancy or lactation

- Patients (male or female) have fertility possibility but not willing to or not to
adopt effective contraception

- With other neurological dysfunction which can cause inaccurate record of the
occurrence of neurotoxicity and severity

- Known or assignment of any of these products to test drugs allergic agent composition

- Doctors think inappropriate for patients with ganglioside medication or estimated
time of less than 6 weeks

- Active infection (determined by the researcher)

- According to the researcher's judgment, there is serious disease to endanger the
safety of patients, or may prevent the patients from completing the study

- Have a clear history of neurological or psychiatric disorders, including epilepsy or
dementia